MAM
GalaxyCard appoints Vinod Arya as head of marketing
Mumbai: FinTech startup GalaxyCard has announced the appointment of Vinod Arya as head of marketing.
Arya will be responsible for overseeing marketing operations and formulating disruptive strategies to make GalaxyCard a game-changing brand in the digital lending market, said the company in a statement.
He is a serial entrepreneur who has founded two startups – the KachchaChittha and Baggies India. With over 10 years of experience, Arya possesses knowledge and expertise in digital marketing.
“Coming from an entrepreneurial background, Vinod always knew the way to crack a company’s success is to fill the minds of people with the brand vision. He has already spearheaded two big giants, particularly in driving business growth and revenue,” said GalaxyCard CEO and founder Amit Kumar. “At GalaxyCard, we have complete faith that he will revolutionize the concept of marketing and take the business growth to new heights.”
Arya is a self-motivated entrepreneur who is consistent with innovating and taking existing marketing to new levels. He holds a bachelor’s degree in computer application, well-versed in digital marketing.
“I am excited to be a part of a company that has already disrupted traditional lending processes,” Arya said. “I look forward to leveraging my experience and reach more target audiences with innovative ideas to drive the company’s growth ambitions.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
